Cytokinetics stock has been having a very unstable market for the last week. The stock was trading at $19.23 as of the last trading session. As of now in the pre-market the stock is skyrocketing by 50%, the price jumped to $29.65. This sudden rise is caused by the company’s announcement of receiving positive results for heart disease treatment.
Results from the second and first two cohorts of the REDWOOD-HCM trial support the initiation of Phase 3 registrational study of CK-3773274 in hypertrophic cardiomyopathy. Results from the first two cohorts of the REDWOOD-HCMM study revealed that treatment with CK-2274 resulted in statistically significant decreases in the average resting heart rate and the post-Valsalve LVOT-G. Most patients treated with CK-274 achieved the target goal of reducing resting LVOT-G by at least 30% at Week 10.
The safety and efficacy of CK-274 in the REDWOOD-HCM trial were generally well tolerated. There were no serious unfortunate moments in the study. In one patient, the left ventricular ejection fraction returned to its baseline within 2 weeks after the end of their treatment.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.